Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks SlumpInvestors Business Daily • 08/26/25
Eli Lilly's weight loss pill orforglipron clears its latest trial, paving way for approvalCNBC • 08/26/25
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesityPRNewsWire • 08/26/25
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with OlomorasibGlobeNewsWire • 08/25/25
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investorsCNBC • 08/24/25
Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other OvervaluedSeeking Alpha • 08/24/25
If I Could Only Buy 1 S&P 500 Stock From Each Sector for the Rest of 2025, I'd Go With These 11 Dividend StocksThe Motley Fool • 08/23/25
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?Zacks Investment Research • 08/22/25
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?The Motley Fool • 08/22/25
Eli Lilly and Company Investors: Company Investigated by the Portnoy Law FirmGlobeNewsWire • 08/21/25
Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.Barrons • 08/20/25
Anne White to Retire as Executive Vice President and President, Lilly NeurosciencePRNewsWire • 08/20/25
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions24/7 Wall Street • 08/20/25